RS57242B1 - [1,2,4]triazolo[4,3-b]piridazini za upotrebu u tretmanu proliferativnih bolesti - Google Patents

[1,2,4]triazolo[4,3-b]piridazini za upotrebu u tretmanu proliferativnih bolesti

Info

Publication number
RS57242B1
RS57242B1 RS20180582A RSP20180582A RS57242B1 RS 57242 B1 RS57242 B1 RS 57242B1 RS 20180582 A RS20180582 A RS 20180582A RS P20180582 A RSP20180582 A RS P20180582A RS 57242 B1 RS57242 B1 RS 57242B1
Authority
RS
Serbia
Prior art keywords
compound
crystal
pharmaceutically acceptable
formula
piperidin
Prior art date
Application number
RS20180582A
Other languages
English (en)
Serbian (sr)
Inventor
Robert Hugh Bradbury
Alfred Arthur Rabow
Michael James Waring
James Francis Mccabe
Steven Christopher Glossop
Arshed Mahmood
Zoe Ann Cotter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of RS57242B1 publication Critical patent/RS57242B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Geology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Geochemistry & Mineralogy (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Fluid Mechanics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20180582A 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]piridazini za upotrebu u tretmanu proliferativnih bolesti RS57242B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
EP15744308.6A EP3174881B1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
RS57242B1 true RS57242B1 (sr) 2018-07-31

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180582A RS57242B1 (sr) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]piridazini za upotrebu u tretmanu proliferativnih bolesti

Country Status (37)

Country Link
US (5) US9944650B2 (OSRAM)
EP (1) EP3174881B1 (OSRAM)
JP (1) JP6592503B2 (OSRAM)
KR (1) KR20170033427A (OSRAM)
CN (1) CN106536524B (OSRAM)
AP (1) AP2017009700A0 (OSRAM)
AU (1) AU2015295120B2 (OSRAM)
BR (1) BR112017001160A2 (OSRAM)
CA (2) CA3185741A1 (OSRAM)
CL (1) CL2017000223A1 (OSRAM)
CO (1) CO2017001918A2 (OSRAM)
CY (1) CY1120602T1 (OSRAM)
DK (1) DK3174881T3 (OSRAM)
DO (1) DOP2017000018A (OSRAM)
EA (1) EA032654B9 (OSRAM)
ES (1) ES2670444T3 (OSRAM)
GT (1) GT201700016A (OSRAM)
HR (1) HRP20180788T1 (OSRAM)
HU (1) HUE037571T2 (OSRAM)
IL (1) IL250104B (OSRAM)
LT (1) LT3174881T (OSRAM)
MX (1) MX374539B (OSRAM)
MY (1) MY187251A (OSRAM)
NI (1) NI201700006A (OSRAM)
NO (2) NO2719005T3 (OSRAM)
PE (1) PE20170527A1 (OSRAM)
PH (1) PH12017500159B1 (OSRAM)
PL (1) PL3174881T3 (OSRAM)
PT (1) PT3174881T (OSRAM)
RS (1) RS57242B1 (OSRAM)
SG (1) SG11201700419SA (OSRAM)
SI (1) SI3174881T1 (OSRAM)
SM (1) SMT201800260T1 (OSRAM)
SV (1) SV2017005368A (OSRAM)
TN (1) TN2017000018A1 (OSRAM)
WO (1) WO2016016618A1 (OSRAM)
ZA (1) ZA201701207B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (OSRAM) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
BR112022007210A2 (pt) 2019-10-14 2022-07-05 Astrazeneca Ab Terapia de combinação para tratar malignidade hematológica
IL294399A (en) 2020-01-09 2022-08-01 Astrazeneca Ab Combination therapy for treating cancer
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
RU2008127263A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) ПИРАЗОЛ [1,5-a] ПИРИДИН-3-КАРБОНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ EphB-И VEGFR2-КИНАЗЫ
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
AU2010212590B2 (en) * 2009-02-10 2013-01-10 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
MX2011012055A (es) * 2009-05-11 2011-12-06 Astrazeneca Ab [1,2,4] triazolo [4,3-b] piridazinas como ligandos del receptor de androgeno.
RS53179B (sr) 2009-11-05 2014-06-30 Glaxosmithkline Llc Benzodiazepinski inhibitor bromodomena
US9328117B2 (en) * 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (OSRAM) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
EP3174881B1 (en) 2018-03-28
SV2017005368A (es) 2017-05-12
TN2017000018A1 (en) 2018-07-04
US20230035133A1 (en) 2023-02-02
NO2719005T3 (OSRAM) 2018-01-20
NI201700006A (es) 2017-08-25
AU2015295120A1 (en) 2017-02-02
US20210107905A1 (en) 2021-04-15
AU2015295120A8 (en) 2017-02-09
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
MY187251A (en) 2021-09-15
DOP2017000018A (es) 2017-03-15
BR112017001160A2 (pt) 2017-11-14
KR20170033427A (ko) 2017-03-24
EP3174881A1 (en) 2017-06-07
PL3174881T3 (pl) 2018-08-31
US20170210747A1 (en) 2017-07-27
CY1120602T1 (el) 2019-12-11
US10407432B2 (en) 2019-09-10
CO2017001918A2 (es) 2017-05-10
JP6592503B2 (ja) 2019-10-16
CA3185741A1 (en) 2016-02-04
CA2956421A1 (en) 2016-02-04
CL2017000223A1 (es) 2017-08-25
US11407755B2 (en) 2022-08-09
EA201790179A1 (ru) 2017-07-31
IL250104B (en) 2018-10-31
US10766905B2 (en) 2020-09-08
IL250104A0 (en) 2017-03-30
NO3174881T3 (OSRAM) 2018-08-25
PT3174881T (pt) 2018-05-25
HRP20180788T1 (hr) 2018-06-29
AU2015295120B2 (en) 2018-02-01
MX374539B (es) 2025-03-06
LT3174881T (lt) 2018-06-11
ZA201701207B (en) 2018-12-19
US20200055861A1 (en) 2020-02-20
EA032654B9 (ru) 2019-07-31
CN106536524A (zh) 2017-03-22
SG11201700419SA (en) 2017-02-27
SMT201800260T1 (it) 2018-07-17
CN106536524B (zh) 2019-11-15
DK3174881T3 (en) 2018-06-06
HUE037571T2 (hu) 2018-09-28
US20180230158A1 (en) 2018-08-16
PH12017500159A1 (en) 2017-07-10
GT201700016A (es) 2018-12-19
ES2670444T3 (es) 2018-05-30
AP2017009700A0 (en) 2017-01-31
CA2956421C (en) 2023-03-14
WO2016016618A1 (en) 2016-02-04
PH12017500159B1 (en) 2020-12-09
EA032654B1 (ru) 2019-06-28
US9944650B2 (en) 2018-04-17
SI3174881T1 (en) 2018-06-29
JP2017522338A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
US20230035133A1 (en) [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases
CN113993873B (zh) 用于治疗癌症的egfr抑制剂
EP2935244B1 (en) Novel benzimidazole derivatives as kinase inhibitors
CA3002608A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CA2749926A1 (en) Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
WO2017194632A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JP7561777B2 (ja) 新規ｅｇｆｒ阻害剤
AU2018234985A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP1581514A2 (en) Chemical compounds
US20100292222A1 (en) Chemical compounds 751
CA3119882A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
CA3119886A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
HK1235059B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
HK1235059A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
BR122024019068A2 (pt) Método de preparação de forma cristalina de (s) -7- (1- acriloilpiperidin- 4-il) -2- (4-fenoxifenil) -4,5,6,7-tetra-hidropirazol [1,5-a] pirimidina- 3-carboxamida
BR122024019067A2 (pt) Forma cristalina de (s) -7- (1-acriloilpiperidin-4-il) -2- (4-fenoxifenil) -4,5,6,7-tetra-hidropirazol [1,5-a] pirimidina-3-carboxamida, sua preparação e seus usos
BR112019003205B1 (pt) Forma cristalina de (s) -7- (1-acriloilpiperidin-4-il) -2- (4-fenoxifenil) -4,5,6,7-tetra-hidropirazol [1,5-a] pirimidina-3-carboxamida, sua preparação e seus usos